Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28680774 | 0.84 | NR4A2 (0.56) | NR4A2HCAR2IDO1AGXTMAOB | |
| SCHEMBL1623271 | 0.83 | FFAR1 (0.49) | NR4A2HCAR2FFAR1 | |
| SCHEMBL5038094 | 0.82 | CTBP2 (0.47) | IDO1FFAR1 | |
| SCHEMBL2343054 | 0.82 | IDO1 (0.47) | IDO1MAOBMMP1MMP2MMP9 | |
| SCHEMBL28344411 | 0.81 | IDO1 (0.69) | NR4A2HCAR2IDO1AGXTMAOB | |
| SCHEMBL7646959 | 0.81 | MEN1 (0.54) | NR4A2HCAR2PPARA | |
| SCHEMBL3254928 | 0.80 | MAOB (0.51) | NR4A2HCAR2IDO1AGXTMAOB | |
| SCHEMBL15152717 | 0.79 | THRA (0.51) | MAOBFFAR1MAOA | |
| SCHEMBL21657315 | 0.79 | FFAR4 (0.44) | FFAR1PPARA | |
| SCHEMBL4217267 | 0.79 | HCAR2 (0.55) | HCAR2IDO1AGXTMAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831614-B | Substituted benzodiazacyclo compound and its preparation method and use | 清华大学 | 2020-07-28 | — | — | CN | disclosed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| EP-2007372-B1 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20090092580-A1 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090092580-A1 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2007121471-A2 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | NR4A2 3294/4885HCAR2 3272/4885IDO1 2763/4885 |
| US-20090092580-A1 | DIALKYL ETHER DELIVERY AGENTS | LIPA, SLC10A1, ABCB11 | NR4A2 1464/4885HCAR2 2746/4885IDO1 4303/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | NR4A2 3294/4885HCAR2 3272/4885IDO1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.